Zynex Inc. (ZYXI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -60.00%. A quarter ago, it was expected that this company would post a loss of $0.2 per share when it actually produced a loss of $0.33, delivering a surprise of -65%.Over the last four quarters, the company has surpassed co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) | NEVADA | 90-0275169 | | --- | --- | ...

Zynex (ZYXI) Q2 2025 Earnings Call July 31, 2025 04:15 PM ET Speaker0Afternoon, ladies and gentlemen, and welcome to the Zynex Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to Dan Moorhead, Chief Financial Officer of Zynix.Please go ahead.Speaker1Thank you, operator, and good a ...

Exhibit 99.1 Zynex Reports Second Quarter 2025 Financial Results ENGLEWOOD, Colo., July 31, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary "In the second quarter of 2025, we completed two transformational events. First, we appoin ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025.  Financial results will be issued in a press release prior to the call.Zynex management will host the con ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - Zynex, Inc. is under investigation for potential claims related to a class action complaint alleging that the company's board of directors breached their fiduciary duties by misleading investors about financial performance and operational practices [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint claims that Zynex's management engaged in practices that artificially inflated the company's stock price through false statements regarding financial performance and compliance with insurance reimbursement policies [2]. - It is alleged that Zynex operated a systemic "oversupplying scheme," shipping excessive quantities of supplies to patients and billing insurers significantly more than necessary [2]. Financial Impact and Regulatory Scrutiny - The extent of Zynex's misconduct was revealed on March 11, 2025, when the company announced a revenue shortfall due to slower payments from insurers, particularly Tricare, which accounted for 20-25% of its annual revenue [3]. - Following the announcement, Zynex's stock price fell by $3.59 per share, or 51.3%, closing at $3.41 per share, indicating a severe loss of shareholder value and highlighting the company's exposure to regulatory and financial risks [4].

Core Insights - Zynex Inc's CEO Thomas Sandgaard announced his decision to step down after nearly 30 years, citing the need for new leadership to continue the company's growth [1][2] - The company has successfully helped over a million patients manage pain and generated hundreds of millions in revenue [2][4] Leadership Transition - Steven Dyson, a seasoned healthcare executive with 25 years of experience, has been identified as the successor and will officially take over in August [3][4] - The decision to transition leadership was influenced by a failed attempt to take Zynex private, which highlighted the need for a fresh perspective to enhance market capitalization and valuation [3][5] Company History and Achievements - Zynex was founded with no initial funding, and Sandgaard faced numerous challenges, including public listings and operational expansion [1][2] - The company achieved a significant milestone by uplisting to the OTC market eight years ago, which was crucial for financing and growth [2][3] - Sandgaard expressed pride in building a strong team and overcoming numerous challenges throughout the company's history [4][5]

Core Viewpoint - Zynex, Inc. continues to face a temporary payment suspension from its largest insurance customer, Tricare, while awaiting a final decision after an appeal [1][2]. Company Overview - Zynex, Inc. is a medical technology company founded in 1996, specializing in non-invasive medical devices for pain management, rehabilitation, and patient monitoring [6]. Recent Developments - The company was notified of a temporary suspension of payments from Tricare, which is currently under review [2]. - Zynex's President and CEO, Thomas Sandgaard, indicated that the company presented data to Tricare officials in April to appeal the suspension [2]. Financial Implications - The continuation of the payment suspension may impact Zynex's financial performance until Tricare reaches a final decision [2].